In yesterday’s Wall Street session, Boston Scientific Corp. (NYSE:BSX) shares traded at $56.48, up 0.95% from the previous session.
30 analysts cover Boston Scientific Corp. (NYSE:BSX), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $67.00 and a low of $52.50, we find $61.00. Given the previous closing price of $55.95, this indicates a potential upside of 9.03 percent. BSX stock price is now 7.07% away from the 50-day moving average and 8.78% away from the 200-day moving average. The market capitalization of the company currently stands at $82.74B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 3 analysts and a buy rating from 21. Brokers who have rated the stock have averaged $60.98 as their price target over the next twelve months.
With the price target of $59, Robert W. Baird recently initiated with Outperform rating for Boston Scientific Corp. (NYSE: BSX).
In other news, Mirviss Jeffrey B., EVP&Pres, Periph Intervent sold 353 shares of the company’s stock on Dec 06. The stock was sold for $19,426 at an average price of $55.03. Upon completion of the transaction, the EVP&Pres, Periph Intervent now directly owns 56,588 shares in the company, valued at $3.2 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 20, EVP& Grp Pres, MedSurg & APAC Butcher Arthur C sold 8,278 shares of the business’s stock. A total of $447,509 was realized by selling the stock at an average price of $54.06. This leaves the insider owning 6,977 shares of the company worth $0.39 million. Insiders disposed of 1,355,997 shares of company stock worth roughly $76.59 million over the past 1 year. A total of 0.43% of the company’s stock is owned by insiders.
On Wednesday morning Boston Scientific Corp. (NYSE: BSX) stock kicked off with the opening price of $56.04. During the past 12 months, Boston Scientific Corp. has had a low of $44.35 and a high of $56.22. As of last week, the company has a debt-to-equity ratio of 0.49, a current ratio of 1.42, and a quick ratio of 0.90. According to the stock market information, the enterprise value for the company is $90.31B, which is based on a 69.18 price-to-earnings ratio, a 5.58 price-to-earnings-growth ratio, and a beta of 0.78. The fifty day moving average price for BSX is $52.75 and a two-hundred day moving average price translates $51.92 for the stock.
The latest earnings results from Boston Scientific Corp. (NYSE: BSX) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at $0.5, beating analysts’ expectations of $0.48 by 0.02. This compares to $0.13 EPS in the same period last year. The net profit margin was 8.66% and return on equity was 6.72% for BSX. The company reported revenue of $3.53 billion for the quarter, compared to $3.17 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.26 percent. For the current quarter, analysts expect BSX to generate $3.59B in revenue.
